1/41
Looks like no tags are added yet.
Intellectual property (IP)
Protection of an invention or discovery.
Invention disclosure
A disclosure to the University of Florida that allows UF to decide whether to file a provisional patent application.
Why disclose an invention?
Without disclosure, research discoveries are rarely commercialized.
Bayh-Dole Act and UF policy
UF employees must disclose intellectual property they create to the Office of Technology Licensing.
UF ownership of intellectual property
UF generally owns intellectual property created by its employees unless it is specifically waived back to the funding agency or inventors.
When does UF have rights to an invention?
When the invention was made while employed at UF and is in the employee's field/discipline, or when it was made using university resources.
Provisional patent application
Provides 12 months before a patent application must be submitted or protection can lapse.
IND
Investigational New Drug application required before initiating clinical trials involving an investigational drug.
Three broad areas of an IND
Animal pharmacology/toxicology studies, manufacturing information, and clinical protocols/investigator information.
Animal pharmacology/toxicology information in an IND
Provides the T0 information supporting the safety of moving the investigational drug into humans.
Clinical protocols/investigator information
Includes detailed protocols for proposed clinical studies to assess whether initial-phase trials will expose subjects to unnecessary risks.
IND 30-day period
After an IND is submitted, the sponsor must wait 30 calendar days before initiating clinical trials so the FDA can review it for safety.
IRB
Institutional Review Board that reviews human research to ensure participants' welfare and rights are protected.
IRB approval requirement
Human research cannot be conducted without prior IRB approval.
Other institutional requirements before Phase I
Informed consent, HIPAA, and blood-borne pathogen training.
Good Clinical Practice (GCP)
Ethical guidelines for designing, recording, and reporting clinical trial results involving human subjects.
Good Manufacturing Practice (GMP)
Guidelines for producing pure, safe, and effective therapeutic agents.
Consequence of violating GCP/GMP
Results may be nullified, requiring the trial to be repeated using the correct procedures before the therapeutic can advance.
Phase I purpose
Establish the maximum-tolerated dose or minimum dose required for full target engagement and define the dose/schedule for Phase II trials.
Phase I secondary endpoints
Optimal route of administration, half-life, bioavailability, target engagement, and therapeutic efficacy if observed.
Phase I therapeutic efficacy
If observed, it is usually not statistically significant because the small sample size makes the study underpowered.
Phase I upside
Provides hope for patients who have exhausted other treatment options.
Phase I downside
Patients experience the highest probability of adverse events with the lowest chance of therapeutic benefit.
Phase I PK
Measures the effects of the body on the drug, including ADME and half-life.
Phase I PD
Measures the effects of the drug on the body, including toxicity, adverse reactions, and maximum-tolerated dose.
Drug half-life
How quickly the drug leaves circulation; helps determine the dosing schedule.
Maximum-tolerated dose (MTD)
The highest dose at which adverse reactions are not observed OR the lowest dose required to fully engage the drug target.
What is the purpose of an invention disclosure?
To allow UF to decide whether to file a provisional patent application and help protect potentially commercializable discoveries.
Why is intellectual property protection important in translational research?
Protecting inventions/discoveries allows them to be developed and potentially commercialized.
What does the Bayh-Dole Act require at UF?
UF employees must disclose intellectual property they create to the Office of Technology Licensing.
How long does a provisional patent application provide before a patent application must be submitted?
12 months.
What is an IND?
An Investigational New Drug application required before initiating clinical trials involving an investigational drug.
What are the three broad areas of an IND?
Animal pharmacology/toxicology studies, manufacturing information, and clinical protocols/investigator information.
Why must a sponsor wait 30 days after submitting an IND?
To give the FDA an opportunity to review the IND for safety and ensure research subjects are not exposed to unreasonable risk.
What must happen before human research can be conducted?
The research must receive prior IRB approval.
What additional institutional requirements are listed before Phase I?
Informed consent, HIPAA, and blood-borne pathogen training.
What is the difference between GCP and GMP?
GCP governs ethical design, recording, and reporting of human clinical trials, while GMP governs production of pure, safe, effective therapeutic agents.
What is the primary endpoint of Phase I?
Establish the MTD or minimum dose required for full target engagement and define the dose/schedule for Phase II.
What are the secondary endpoints of Phase I?
Route of administration, half-life, bioavailability, target engagement, and therapeutic efficacy if observed.
Why is therapeutic efficacy usually not statistically significant in Phase I?
Phase I has a small sample size and is therefore usually underpowered to detect statistically significant efficacy.
What are the major PK measurements in Phase I?
Absorption, distribution, metabolism, excretion, and half-life.
What are the major PD measurements in Phase I?
Toxicity, adverse reactions, and maximum-tolerated dose.